FDA Clears Modular Medical's Pivot Software Upgrades Ahead of Q4 Launch
MODD has more than doubled off its 52-week low of $1.72.
Summary
Modular Medical received FDA clearance for software enhancements to its Pivot insulin delivery system, including customizable bolus dosing and UI improvements. The clearance arrives ahead of the planned Q4 commercial launch and follows the company's July FDA submission. This is a key regulatory milestone that de-risks the upcoming launch and supports the commercialization strategy across five U.S. markets. Shares rose 6.94% premarket to $3.70 on the news. The company remains in a liquidity-constrained position, with ongoing ATM sales and a recent $6.5M quarterly loss, so successful commercialization is critical.
At the time of this announcement, MODD was trading at $3.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.2M. The 52-week trading range was $1.72 to $30.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.